Merck Animal Health
ثبت نشده
چکیده
Lancaster R.T., Foxcroft, G.R., Boland, M.R, Edwards, S. and Gordon, I., 1985. Fertility of sows treated with exogenous estradiol and/or gonadotropins to control postweaning estrus. Anim. Reprod. Sci., 8:365-373 In the first of two experiments 28 multiparous sows were allocated to one of the following treatments two days after weaning at approximately 35 days postpartum: (1) untreated; (2) i.m. injection 10 μg estradiol benzoate (OB)/kg body weight (b. wt.); and (3) i.m. injection 20 μg OB/kg b. wt. Sows were bred at first post-weaning estrus and ovulation rate assessed at slaughter. The mean interval from weaning to estrus in each group was: (1) 5.6 ± 0.2; (2) 4.7 ± 0.2; and (3) 4.7 ± 0.2 days; the mean ovulation rates in groups 1 and 2 (18.7 ± 0.6 and 17.4 ± 1.8, respectively) were significantly higher (P < 0.01) than that of 12.0 ± 1.7 for treatment three sows. Two untreated and one each of the treated sows were not cycling at slaughter. In the second experiment 75 multiparous sows weaned at 28 ± 3 days postpartum (day 0) were evenly allocated with respect to parity to one of four treatment groups: (1) untreated; (2) i.m. injection 10 μg OB/kg b. wt. on day two; (3) P.G. 600 (400 I.U. PMSG + 200 I.U. HCG) injection subcutaneous day 0; and (4) combined P.G. 600/OB treatment as in (2) and (3) above. Sows were bred naturally at the first post-weaning estrus and fertility assessed at farrowing. Control animals had a significantly longer (P < 0.05 weaning to estrus interval (4.53 ± 0.25 days) compared to treatment 2 (4.03 ± 0.13), treatment 3 (3.97 ± 0.12) and treatment 4 (3.81 ± 0.07) sows. Sows treated with P.G. 600 alone showed a significant increase (P < 0.05) in numbers born live compared to pre-treatment values. A smaller and nonsignificant increase in numbers born live in control sows (probably related to increasing parity) was not observed in either OB or P.G. 600/OB-treated animals. These results suggest that with further modification of the treatments, a system may be developed for introducing fixed-time artificial insemination (AI) or mating as a means of controlling the reproductive performance of the weaned sow.
منابع مشابه
1051Well-child Visits and HPV Vaccination Rates in Privately Insured Females Aged 9-21 Years in the United States, 2007-2012
Females Aged 9-21 Years in the United States, 2007-2012 Dongmu Zhang, PhD; Nagesh N. Borse, PhD, MS, BS Pharm; Amit S. Kulkarni, PhD; Linda Niccolai, PhD ScM; Global Health Outcomes, Merck and Co. Inc., West Point, PA; Global Health Outcomes, Agile 1 For Merck and Co., West Point, PA; Global Health Outcomes Vaccine, Merck and Co. Inc., Whitehouse Station, NJ; Yale School of Public Health, Yale ...
متن کاملImpaired immune response to vaccination against infection with 3 human respiratory syncytial virus at advanced age
5 Teun Guichelaar#, Jeroen Hoeboer, Myra N. Widjojoatmodjo, Sylvia S.N. Reemers, Cécile 6 A.C.M. van Els, Rob Otten, Yvonne van Remmerden, Jolande Boes, Willem Luytjes 7 8 Centre for Immunology of Infectious Diseases and Vaccinology, National Institute for Health 9 and the Environment, 3720 BA Bilthoven, The Netherlands 10 11 Present address: Crucell, Leiden, The Netherlands 12 Present address:...
متن کاملThe case of ivermectin: lessons and implications for improving access to care and treatment in developing countries.
On October 21, 1987, Merck & Co., Inc., announced plans to donate Mectizan (ivermectin), a new medicine designed to combat onchocerciasis (Ôriver blindnessÕ), for as long as it might be needed. Merck took this action, working in col laboration with international experts in parasitology, the World Health Organization, and other agencies to reach those affected by the illness. This unusual decisi...
متن کاملAn Expert Consortium Review of the EC - commissioned Report “ Alternative ( Non - Animal ) Methods for Cosmetics Testing : Current Status and Future Prospects – 2010 ” *
An Expert Consortium Review of the EC-commissioned Report “Alternative (Non-Animal) Methods for Cosmetics Testing: Current Status and Future Prospects – 2010”* Thomas Hartung , Bas J. Blaauboer , Sieto Bosgra , Edward Carney , Joachim Coenen , Rory B. Conolly , Emanuela Corsini , Sidney Green , Elaine M. Faustman , Anthony Gaspari , Makoto Hayashi , A. Wallace Hayes , Jan G. Hengstler , Lisbeth...
متن کامل1046Economic Burden of Herpes Zoster by Age Group in Immunocompetent Patients in the United States
Immunocompetent Patients in the United States Justin Gatwood, MPH; Barbara Johnson, MBA; Liisa Palmer, PhD; Gregory Lenhart, MS; Kosuke Kawai, ScD, SM; Camilo Acosta, PhD, MSc; Custom Data Analytics, Truven Health Analytics, Durham, NC; Outcomes Research, Truven Health Analytics, Cambridge, MA; Outcomes Research, Truven Health Analytics, Bethesda, MD; Global Health Outcomes Vaccines, Merck and ...
متن کاملSocial benefits of a successful biomedical research company: Merck.
HE PHARMACEUTICAL INDUSTRY has as its objective the discovery of important new medicines and vaccines to prevent and alleviate diseases and to improve health and the quality of life. Merck has been doing that successfully since 1933, when George W. Merck opened the first laboratory in Rahway, New Jersey. Through the efforts of its research scientists, the company has contributed drugs and vacci...
متن کامل